{"preliminary_commentary":{"by_channel":{"bluesky_thread":4,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"BBOpCo","nct_id":"NCT06268015","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bbopco-nct06268015. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BBOpCo","arms":[{"description":"botensilimab + balstilimab until disease progression, then botensilimab + balstilimab + mFOLFOX6 (leucovorin, fluorouracil, oxaliplatin) + {bevacizumab or panitumumab}","label":"Treatment","type":"EXPERIMENTAL"}],"collaborators":["Gateway for Cancer Research","Agenus Inc."],"completion_date":{"date":"2028-07","type":"ESTIMATED"},"conditions":["Colorectal Cancer"],"enrollment":{"count":16,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Botensilimab","otherNames":[],"type":"DRUG"},{"name":"Balstilimab","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"Leucovorin","otherNames":[],"type":"DRUG"},{"name":"Fluorouracil","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"Panitumumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-05","lead_sponsor":"Nicholas DeVito, MD","official_title":"Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease control rate based on iRECIST at second restaging scan","timeFrame":"24 weeks after screening"},{"measure":"Proportion of subjects with a best overall response of complete response or partial response according to iRECIST","timeFrame":"up to 2 years"}],"references":[],"start_date":{"date":"2024-11-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Botensilimab and Balstilimab Optimization in Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT06268015"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bbopco-nct06268015"}